FiercePharma15h
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
FiercePharma10h
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...
FiercePharma15h
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
FiercePharma15h
Cosette sets sights on women's healthcare stardom with $430M Mayne Pharma buy
With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...
FiercePharma17h
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
FiercePharma15h
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
FiercePharma11h
Abbott's stigma-busting campaign shows how diabetes biases lead to silence, skipped care
A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal ...
FiercePharma16h
PMCPA brings the buzzkill to LinkedIn celebration, laying into GSK over employee’s clicks
The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...